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BCR-ABL-mediated leukemias, either Chronic Myeloid Leukemia (CML) or Philadelphia positive Acute Lymphoblastic Leukemia
(ALL), are the paradigm of targeted molecular therapy of cancer due to the impressive clinical responses obtained with BCR-
ABL specific tyrosine kinase inhibitors (TKIs). However, BCR-ABL TKIs do not allow completely eradicating both CML and ALL.
Furthermore, ALL therapy is associated with much worse responses to TKIs than those observed in CML. The identification of
additional pathways that mediate BCR-ABL leukemogenesis is indeed mandatory to achieve synthetic lethality together with TKI.
Here, we review the role of BCR-ABL/protein kinase CK2 interaction in BCR-ABL leukemias, with potentially relevant implications
for therapy.
1. Introduction
The t(9;22) chromosomal translocation (also known as
Philadelphia chromosome, or Ph+) is the genetic hallmark
of Chronic Myeloid Leukemia (CML) and characterizes one
quarter of adult Acute Lymphoblastic Leukemia (ALL) and
less than 5% of pediatric ALL [1–4]. CML is sustained by
the p210-BCR-ABL isoform, while Ph+-ALL is driven by a
shorter p190-BCR-ABL isoform [5]. BCR-ABL leukemias are
the paradigm of cancer targeted therapy, due to the successful
development of BCR-ABL specific tyrosine kinase inhibitors
(TKIs). However, CML and Ph+-ALL still challenge clinicians
and biologists. Clinicians are facing the fact that CML is
still an uncurable disease [6]. Even if CML is effectively
targeted by TKIs with astonishing responses rates, most
of those patients that discontinue TKI therapy eventually
relapse [7] due to the persistence of TKI resistant CML stem
cells [8–11]. The second, Ph+-ALL, is associated with much
worse responses to TKI than those observed in CML [1, 12]
and therefore requires additional targets to achieve synthetic
lethality together with TKI. Furthermore, clinicians have also
to address the issue of TKI resistance due to the development
of BCR-ABL pointmutations [13].Therefore, the definition of
those pathways that are necessary for the maintenance of Ph+
leukemias could identify novel targets to achieve synthetic
lethality together with TKI. Here, we will review the role of
protein kinase CK2 (Casein Kinase 2, CK2 from here on) as a
BCR-ABL substrate.
2. Protein Kinase CK2
2.1. Biological Characterization. CK2 is an ubiquitously
expressed serine-threonine kinase [14–21]. It is composed
of two catalytic and two regulator subunits. The catalytic
units are represented by the isoforms CK2𝛼 and CK2𝛼󸀠;
the regulatory unit is composed of the CK2𝛽 isoform. Each
subunit is the product of different genes. The relevance of
CK2 in biological processes is highlighted by the phenotype
of CK2 knockout mice. In particular, both CK2𝛼 [22, 23]
and CK2𝛽 [24] knockout mice are lethal with multiple
embryonic alterations; however, knockout mice of CK2𝛼󸀠
are viable [25], although sterile, suggesting some grade of
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Figure 1: Protein kinase CK2 targets. This figure summarizes major CK2 targets.
compensations among the CK2 catalytic subunits. The CK2𝛽
subunit is highly conserved among species and is involved
in the assembly of the tetrameric complex with the catalytic
subunits and in the modulation of substrate recognition.
Two CK2𝛽 interact with two identical (two CK2𝛼 or two
CK2𝛼󸀠) or nonidentical (one CK2𝛼 and one CK2𝛼󸀠) cat-
alytic subunits. The CK2 kinase is able to phosphorylate
serine or threonine residues in proteins bearing a minimal
consensus sequence that contains an acidic residue (Glu,
Asp, pSer, or pTyr). CK2 is a unique kinase in that it can
utilize GTP as well as ATP as the phosphate donor [19].
CK2 was often referred to as a constitutively active kinase,
although several reports suggested different chances of kinase
modulation [26]. In particular, it was extensively reviewed
that CK2 activity can bemodulated by changes in the subunit
assembly, interaction with different regulatory elements, and
protein interaction and finally even through different levels of
phosphorylation/autophosphorylation [16, 19, 26, 27]. Several
phosphorylation residues have indeed been identified both
in the catalytic and regulatory subunits. Even if these phos-
phorylation sites did not appear to directly affect the kinase
activity, these sites could affect the stability of the tetramer
and therefore regulate substrate phosphorylation.
2.2. CK2 Targets. Beside the complex mechanisms of CK2
regulation and activation, which still require further inves-
tigations, it is well documented that CK2 phosphorylates
several different targets, as extensively reviewed [18, 28].
CK2 was discovered in each cellular compartment, from the
membrane to the nucleus, suggesting that it can interact and
regulate the function of several proteins in every cellular
compartment. In particular, CK2 is known to regulate cellular
proliferation and apoptosis, DNA damage repair and gene
expression, regulation of cell structure, and other cellular
processes. Figure 1 shows some of the cancer associated
targets, such as AKT, IkB-𝛼, STAT5, and 𝛽-catenin.
2.3. CK2 Inactivates PTEN. PTEN is a tumor suppressor
that negatively regulates the PI3K-AKT pathway, therefore
counteracting one of the major signaling transduction net-
works involved in cancer pathogenesis [29, 30]. PTEN func-
tion is regulated by several posttransductional modifications
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such as serine/threonine-phosphorylation, acetylation, ubiq-
uitination, and sumoylation [30]. Notably, the C-terminal
domain of PTEN contains six serine/threonine residues
(Thr-366; Ser-370; Ser-380; Thr-382; Thr-383 and Ser-385)
that regulate the activity of the phosphatase PTEN, cellular
compartmentalization, and protein stability [31–35]. Even if
Ser-370 and Ser-385 were identified by mass-spectrometry as
the mostly phosphorylated sites in PTEN [36, 37], all these
residues have been described as CK2 substrates. Notably,
CK2-mediated PTEN tail phosphorylation was clearly shown
to play a role in different Philadelphia chromosome negative
leukemias [38–42].
3. CK2 Inhibitors
Several CK2 inhibitors have been developed with different
grades of selectivity and potency, as extensively reported
[17, 43–54]. CK2 inhibitors have already been tested in
hematological cancers. In particular, Chronic Lymphocytic
Leukemia has been extensively studied for its high sensi-
tiveness to CK2 inhibitors [41, 55]. Similarly, CK2 inhibitors
appeared to display important effects in T-ALL [56]. Cur-
rently, some clinical trials are ongoing and will assess the
relevance of CK2 inhibitors in the setting of hematological
and solid cancers.
4. CK2 in Philadelphia Positive Leukemias
An original report showed that CK2 is highly expressed in
proliferating CML myeloid progenitors [57]. Later, it was
shown that BCR-ABL is able to physically interact with
CK2𝛼 in K562 cell line, via the ABL portion of the chimeric
protein [58]. Similarly, CK2𝛼 was shown to interact with c-
Abl in NIH3T3 cells. Furthermore, BCR-ABL appeared to
phosphorylate CK2𝛼 on tyrosine residues. Notably, in this
first report, BCR-ABL was shown to inhibit the function of
CK2𝛼 [58]. BCR-ABL/CK2𝛼 interactionwas also investigated
by another group [59], who demonstrated that CK2𝛼 strongly
interacts with the BCR region between amino acids 242
and 413. Oppositely to the first report, CK2𝛼 was shown
to positively mediate BCR-ABL signaling in both CML
and Ph+-ALL [59]. Treatment with CK2𝛼 inhibitor 4,5,6,7-
tetrabromo-2-benzotiazole was indeed shown to inhibit the
growth of both p210- and p190-BCR-ABL transformed cells
and BCR-ABL positive cells. Notably, the inhibition of BCR-
ABL with TKI is also associated with the reduction of CK2𝛼
serine/threonine kinase activity. These original observations
offer important implications for the therapeutical approach of
BCR-ABL-positive CML/ALL and for the definition of CK2
regulation mechanisms. In particular, while CK2 has always
been referred to as a constitutively active kinase, this work
demonstrated that BCR-ABL regulates CK2 kinase activity,
even if through a complex yet unknownmechanism. Another
report further highlights the utility of targeting CK2 in the
setting of BCR-ABL-mediated leukemias and in particular
p190-BCR-ABL ALL cells [60]. A great step forward in the
understanding of the role of BCR-ABL/CK2 complex was
carried out by the group of Donella-Deana [61]. In particular,
while the first two reports lead to opposite conclusions, prob-
ably due to different cellular context, the last report confirmed
that BCR-ABL interacts with CK2𝛼 in CML cells and that
this interaction promotes cellular proliferation. Furthermore,
this work provided additional insights on the mechanisms
of CK2𝛼 regulation by BCR-ABL. In particular, authors have
shown that CK2, both CK2𝛼 and CK2𝛽, may be upregulated
in imatinib-resistance CML cell lines with a consequent
increase in the CK2 kinase activity [61]. Notably, no changes
on the mRNA levels were observed, clearly suggesting
upstream CK2 regulation.This observation, and the previous
observation that CK2𝛼 tyrosine phosphorylation by BCR-
ABL affects theCK2 kinase activity, suggests that inCMLCK2
not only is just a constitutively active kinase but also can be
somehow regulated. To further investigate the mechanisms
of interaction, authors have also confirmed that BCR-ABL
tyrosine phosphorylates CK2 and that this event is not
required for the interaction between the two kinases. How-
ever, inhibition of CK2 abrogates the interaction. Although
these data did not shed light on the complex mechanism
of CK2 regulation, it is clear that BCR-ABL is able to force
CK2 to modulate proliferation/survival in Ph+ leukemias.
The authors have indeed clearly confirmed that CK2 inhibitor
CX-4945 is able to promote cell death [61]. All these works
did not link BCR-ABL/CK2𝛼 interaction with specific CK2𝛼
targets [58–60]. Recently, we have demonstrated that BCR-
ABL/CK2𝛼 promotes serine phosphorylation of PTEN tail
[62] (Figure 2). PTEN is found mostly in the cytosol of
CML progenitor cells [63] where it is highly phosphorylated
by CK2. PTEN tail phosphorylation inhibits its phosphatase
activity both in cellular models and in primary CML cells.
Interestingly, PTEN mutants, unable to be phosphorylated
by CK2𝛼, restored the phosphatase activity and were able to
promote strong apoptosis induction in CML cells. Altogether,
these works demonstrate that BCR-ABL interacts with CK2𝛼
which is in turn tyrosine phosphorylated [58, 59, 61]; BCR-
ABL somehow “activates” CK2𝛼 towards substrates that are
involved in the regulation of proliferation and survival. Lastly,
BCR-ABL/CK2𝛼 interaction promotes the phosphorylation
of PTEN with consequent inactivation of its phosphatase
activity [62].
5. Conclusions
Since the discovery of the t(9;22) translocation, the Philadel-
phia chromosome, as the hallmark of CML, this disease has
been the paradigm of precision medicine. However, BCR-
ABL targeting with TKI did not allow eradicating both CML
and Ph+-ALL, therefore highlighting the need of combina-
tional therapies. In this review, we have summarized the
role of CK2 as an essential mediator of BCR-ABL oncogenic
signal. The BCR-ABL/CK2 complex is indeed responsible
for mediating BCR-ABL induced cellular proliferation and
survival. Targeting CK2 with specific inhibitors has been
clearly shown to achieve synthetic lethality togetherwithTKI,
suggesting that a combinatorial therapy could help in erad-
icating Ph+ leukemias. Finally, the intriguing role of BCR-
ABL/CK2 complex as being able to functionally inactivate
the tumor suppressor PTEN may point to a highly effective
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Figure 2: BCR-ABL/CK2/PTEN pathway. This figure describes the BCR-ABL/CK2/PTEN pathway.
proapoptotic therapy even in those cases characterized by
TKI resistance due to BCR-ABL mutations.
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